Yung Shin International Holding Co., Ltd.: Q1 2026 EPS of 0.89 NTD
Key facts
- Yung Shin International Holding Co., Ltd.: Q1 2026 EPS of 0.89 NTD
- Yung Shin International Holding Co., Ltd. announced its financial results for the first quarter of 2026, reporting earnings per share (EPS) of 0.89 NTD. This indicates solid performance and stable growth within the biotechnology and medical industry.
- Source: PR Times
- Date: March 1, 2026
Direct answer
Yung Shin International Holding Co., Ltd. announced its financial results for the first quarter of 2026, reporting earnings per share (EPS) of 0.89 NTD. This indicates solid performance and stable growth within the biotechnology and medical industry.
- Citation
- Yung Shin International Holding Co., Ltd.: Q1 2026 EPS of 0.89 NTD (March 1, 2026), PR Times
- Source
- PR Times
- Date
- March 1, 2026
Yung Shin International Holding Co., Ltd. announced its financial results for the first quarter of 2026, reporting earnings per share (EPS) of 0.89 NTD. This indicates solid performance and stable growth within the biotechnology and medical industry.
📋 Article Processing Timeline
- 📰 Published: March 1, 2026 at 09:00
- 🔍 Collected: May 9, 2026 at 08:00 (1655h 0m after Published)
- 🤖 AI Analyzed: May 9, 2026 at 08:02 (2 min after Collected)
Company Name: Yung Shin International Holding Co., Ltd.
Industry: Biotechnology and Medical Industry
Fiscal Year/Quarter: Q1 2026
Basic Earnings Per Share (EPS): 0.89 NTD
Operating Revenue: 1.841 billion NTD
Net Profit After Tax: 0.253 billion NTD
FAQ
What are the key facts in this article?
Yung Shin International Holding Co., Ltd. announced its financial results for the first quarter of 2026, reporting earnings per share (EPS) of 0.89 NTD. This indicates solid performance and stable growth within the biotechnology and medical industry.
What is the direct answer?
Yung Shin International Holding Co., Ltd. announced its financial results for the first quarter of 2026, reporting earnings per share (EPS) of 0.89 NTD. This indicates solid performance and stable growth within the biotechnology and medical industry.
What is the source and date?
PR Times: https://openapi.twse.com.tw/financial/twse-fin-3705-2026Q1 | March 1, 2026